Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - metrafenone - suspension concentrate - metrafenone uv screen active 500.0 g/l - fungicide - cucurbit | grapevine | cantaloupe | choko | cucumber | gherkin | honeydew melon | marrow | melon | muskmelon | pumpkin | rockmel - powdery mildew

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - metrafenone - unknown - metrafenone uv screen active 0.0 - active constituent

New Zealand - English - Ministry for Primary Industries

basf new zealand limited - metrafenone - metrafenone 500 g/litre - fungicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

crop care - metrafenone(500g/l) - suspension - group u8 fungicide - cucurbit | grapevine | cantaloupe | choko | cucumber | gherkin | honeydew melon | marrow | melon | muskmelon | pumpkin | rockmel - powdery mildew

United States - English - NLM (National Library of Medicine)

anazaohealth corporation - mebrofenin (unii: 7pv0b6ed98) (mebrofenin - unii:7pv0b6ed98) - mebrofenin 10 mg - technetium tc-99m mebrofenin by intravenous administration is indicated as a hepatic imaging agent, used in the diagnosis of liver disease

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - mebrofenin (unii: 7pv0b6ed98) (mebrofenin - unii:7pv0b6ed98) - mebrofenin 45 mg in 10 ml - technetium tc 99m mebrofenin is indicated as a hepatobiliary imaging agent. hypersensitivity to this compound.

United States - English - NLM (National Library of Medicine)

bracco diagnostics inc - mebrofenin (unii: 7pv0b6ed98) (mebrofenin - unii:7pv0b6ed98) - mebrofenin 45 mg - technetium tc 99m mebrofenin is indicated as a hepatobiliary imaging agent. hypersensitivity to this compound.

Ireland - English - HPRA (Health Products Regulatory Authority)

mediam - mebrofenin - powder for solution for injection - n/a - technetium (99mtc) mebrofenin

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b, quantity: 0.25 mg/ml - injection, powder for - excipient ingredients: albumin; mannitol - betaferon is indicated for the treatment of: - ambulatory patients with relapsing-remitting multiple sclerosis (ms) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. - betaferon is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive multiple sclerosis. - the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - interferon beta-1b 0.25mg (20% excess in quantity filled) - injection with diluent - 8 miu - active: interferon beta-1b 0.25mg (20% excess in quantity filled) excipient: albumin hydrochloric acid mannitol sodium hydroxide hydrochloric acid sodium chloride water for injection - betaferon is indicated for: · the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded, · the treatment of ambulatory patients, with relapsing-remitting multiple sclerosis characterised by at least two attacks of neurological dysfunction over a two year period followed by complete or incomplete recovery. · the reduction of frequency and severity of clinical relapses and for slowing the progression of disease in patients with secondary progressive multiple sclerosis